← Back to Screener
Pulmonx Corporation Common Stock (LUNG)
Price$1.53
Value ScoreA
Growth ScoreC
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-13.48%
Price vs S&P 500 (4W)21.44%
VGM Score56.53
Market Capitalization$64.62M
All Metrics
Book Value / Share (Quarterly)$1.08
P/TBV (Annual)3.12x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)19.03%
Cash Flow / Share (Quarterly)$-0.70
Price vs S&P 500 (YTD)-38.93%
Gross Margin (TTM)75.49%
Net Profit Margin (TTM)-60.09%
EPS (TTM)$-1.29
10-Day Avg Trading Volume0.32M
EPS Excl Extra (TTM)$-1.29
Revenue Growth (5Y)22.56%
EPS (Annual)$-1.33
ROI (Annual)-59.21%
Gross Margin (Annual)74.19%
Net Profit Margin (5Y Avg)-85.17%
Cash / Share (Quarterly)$1.46
Revenue Growth QoQ (YoY)-8.66%
ROA (Last FY)-41.77%
Revenue Growth TTM (YoY)1.23%
EBITD / Share (TTM)$-1.24
ROE (5Y Avg)-56.08%
Operating Margin (TTM)-58.79%
Cash Flow / Share (Annual)$-0.79
P/B Ratio1.41x
P/B Ratio (Quarterly)1.19x
Net Income / Employee (Annual)$-182,400
EV / Revenue (TTM)0.46x
Net Interest Coverage (TTM)-45.91x
ROA (TTM)-39.80%
EPS Incl Extra (Annual)$-1.33
Current Ratio (Annual)5.07x
Quick Ratio (Quarterly)3.87x
3-Month Avg Trading Volume0.49M
52-Week Price Return-48.48%
Revenue / Employee (TTM)$299,100
Tangible BV / Share (Quarterly)$2.16
P/S Ratio (Annual)0.71x
Asset Turnover (Annual)0.70x
52-Week High$3.88
Operating Margin (5Y Avg)-85.07%
EPS Excl Extra (Annual)$-1.33
CapEx CAGR (5Y)-13.06%
26-Week Price Return-5.56%
Quick Ratio (Annual)4.15x
13-Week Price Return-4.97%
Total Debt / Equity (Annual)0.69x
Current Ratio (Quarterly)4.91x
Enterprise Value$40.36M
Revenue / Share Growth (5Y)19.39%
Asset Turnover (TTM)0.66x
Book Value / Share Growth (5Y)-27.16%
Revenue / Employee (Annual)$305,700
Inventory Turnover (Annual)1.43x
Pretax Margin (Annual)-58.98%
Cash / Share (Annual)$1.67
3-Month Return Std Dev90.22%
Gross Margin (5Y Avg)74.00%
Net Income / Employee (TTM)$-179,800
ROE (Last FY)-99.79%
Net Interest Coverage (Annual)-46.24x
EPS Basic Excl Extra (Annual)$-1.33
Receivables Turnover (TTM)7.14x
Total Debt / Equity (Quarterly)0.82x
EPS Incl Extra (TTM)$-1.29
Receivables Turnover (Annual)7.18x
ROI (TTM)-56.36%
P/S Ratio (TTM)0.73x
Pretax Margin (5Y Avg)-84.48%
Revenue / Share (Annual)$2.22
Tangible BV / Share (Annual)$2.16
Price vs S&P 500 (52W)-72.85%
Year-to-Date Return-30.77%
5-Day Price Return-3.77%
EPS Normalized (Annual)$-1.33
ROA (5Y Avg)-32.35%
Net Profit Margin (Annual)-59.67%
Month-to-Date Return-7.27%
Cash Flow / Share (TTM)$-1.58
EBITD / Share (Annual)$-1.29
Operating Margin (Annual)-59.30%
LT Debt / Equity (Annual)0.68x
ROI (5Y Avg)-40.34%
LT Debt / Equity (Quarterly)0.81x
EPS Basic Excl Extra (TTM)$-1.29
P/TBV (Quarterly)3.12x
P/B Ratio (Annual)1.68x
Inventory Turnover (TTM)1.31x
Pretax Margin (TTM)-59.37%
Book Value / Share (Annual)$1.30
Price vs S&P 500 (13W)-13.22%
Beta0.28x
Revenue / Share (TTM)$2.11
ROE (TTM)-92.94%
52-Week Low$1.13
vGradeA
gGradeC
mGradeD
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.33est. -0.33
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.00
4.00
4.00
4.00
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LUNGPulmonx Corporation Common Stock | A | C | D | $1.53 |
| SYKStryker Corporation | C | C | C | $305.66 |
| MMM3M Company | C | F | C | $153.76 |
| BSXBoston Scientific Corp. | C | B | D | $48.55 |
| MDLNMedline Inc. Class A common stock | C | D | D | $33.61 |
| BDXBecton, Dickinson and Co. | B | C | C | $151.16 |
| RMDResMed Inc. | C | B | C | $196.04 |
| DXCMDexCom, Inc. | C | B | C | $72.86 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $314.50 |
| SOLVSolventum Corporation | C | D | B | $81.01 |
| PENPenumbra, Inc. | F | C | B | $320.53 |
About
Pulmonx develops minimally invasive treatments for severe emphysema and COPD, with its flagship Zephyr Endobronchial Valve supported by diagnostic assessment platforms. The company sells its medical devices to hospitals and distributors across the U.S., Europe, Middle East, Africa, and Asia Pacific. Pulmonx serves patients with limited treatment options in a significant respiratory disease market.